Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Clin Cancer Res. 2018 Jul 6;24(20):4988–4996. doi: 10.1158/1078-0432.CCR-18-0786

Fig. 3.

Fig. 3

Uptake of 89Zr-AMG211 in LS174T (n = 6), BT474 (n = 6) or HL-60 (n = 6) tumor bearing mice. A) Representative coronal small-animal PET images up to 24 hours after injection of 10 µg 89Zr-AMG211. Li = liver; K = kidney; T = tumor. B) Quantification of tumors (upper panel) and blood pool (lower panel). Ex vivo C) biodistribution and D) SDS-PAGE autoradiography 89Zr-AMG211 24 hours after injection. + : 89Zr-AMG211 prior to injection; - : free 89Zr only; tumor: lysates of 3 different tumor bearing mice; plasma: plasma samples from corresponding mice. Data are mean ± SD. * P ≤ 0.05; ** P ≤ 0.01.